Summit Therapeutics (SMMT) EBITDA Margin (2017 - 2022)
Summit Therapeutics (SMMT) posted quarterly EBITDA Margin of 7700.0% for Q3 2022, down 621138.0% year-on-year from N/an in Q3 2021, and down 42.57% on a QoQ basis from 5400.85% in Q2 2022.
Summit Therapeutics (SMMT) EBITDA Margin (2017 - 2022) Analysis & Trends
Summit Therapeutics (SMMT) has reported EBITDA Margin for 6 consecutive years, with 7700.0% the latest figure, recorded in Q3 2022.
- Quarterly EBITDA Margin fell 621138.0% year-over-year to 7700.0% in Q3 2022, while the trailing twelve-month figure through Jun 2023 was 268266.82% (down 26433611.0% YoY) and the FY2022 annual result came in at 10225.39%, down 546110.0% from the prior year.
- EBITDA Margin declined to 7700.0% in Q3 2022 per SMMT's latest filing, from 5400.85% in the prior quarter.
- Over the last five years, EBITDA Margin for SMMT reached as high as 21.93% in Q3 2018 and fell as low as 41631.58% in Q2 2021.
- A 5-year average of 7868.17% and a median of 6328.1% in 2020 frame the typical range for EBITDA Margin.
- Annual changes were most pronounced in 2021 — EBITDA Margin plunged 3259864 bps — and 2022, when it jumped 3623073 bps.
- Year by year, EBITDA Margin stood at 3288.59% in 2018, then jumped by 100 bps to 14.18% in 2019, then tumbled by 44136 bps to 6246.49% in 2020, then sank by 66 bps to 10377.29% in 2021, then gained by 26 bps to 7700.0% in 2022.
- According to Business Quant data, EBITDA Margin over the past three periods registered 7700.0%, 5400.85%, and 8863.2% for Q3 2022, Q2 2022, and Q1 2022 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 16.51% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 38.10% |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 17.83% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 31.68% |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Summit Therapeutics | 11.62 Bn | 11.03 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2022 | -7,700.00% |
| Jun 30, 2022 | -5,400.85% |
| Mar 31, 2022 | -8,863.20% |
| Dec 31, 2021 | -10,377.29% |
| Sep 30, 2021 | -1,488.62% |
| Jun 30, 2021 | -41,631.58% |
| Mar 31, 2021 | -8,814.06% |
| Dec 31, 2020 | -6,246.49% |
| Sep 30, 2020 | -9,359.67% |
| Jun 30, 2020 | -9,032.94% |
| Mar 31, 2020 | -6,409.72% |
| Dec 31, 2019 | 14.18% |
| Oct 31, 2019 | -15,553.23% |
| Sep 30, 2019 | -4,182.43% |
| Jul 31, 2019 | -13,157.94% |
| Mar 31, 2019 | -4,578.93% |
| Oct 31, 2018 | -3,288.59% |
| Jul 31, 2018 | 21.93% |
| Apr 30, 2018 | -529.35% |
| Jan 31, 2018 | -784.70% |